Compare NMR & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NMR | EXAS |
|---|---|---|
| Founded | 1925 | 1995 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.7B | 19.3B |
| IPO Year | 1961 | N/A |
| Metric | NMR | EXAS |
|---|---|---|
| Price | $8.42 | $101.64 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $77.94 |
| AVG Volume (30 Days) | 977.9K | ★ 5.2M |
| Earning Date | 02-04-2026 | 11-03-2025 |
| Dividend Yield | ★ 3.94% | N/A |
| EPS Growth | ★ 36.89 | N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $13,470,548,516.00 | $3,082,033,000.00 |
| Revenue This Year | $2.08 | $19.40 |
| Revenue Next Year | N/A | $13.51 |
| P/E Ratio | $9.87 | ★ N/A |
| Revenue Growth | 11.80 | ★ 14.47 |
| 52 Week Low | $4.86 | $38.81 |
| 52 Week High | $8.50 | $102.66 |
| Indicator | NMR | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 68.04 | 85.15 |
| Support Level | $8.30 | $101.45 |
| Resistance Level | $8.40 | $101.88 |
| Average True Range (ATR) | 0.10 | 0.36 |
| MACD | 0.00 | -1.35 |
| Stochastic Oscillator | 85.71 | 68.50 |
Nomura Holdings Inc is a financial services group in Japan and operates offices in countries and regions world-wide, including Japan, the U.S., the U.K., Singapore, and the Hong Kong Special Administrative Region ("Hong Kong") through its subsidiaries. The company's clients include individuals, corporations, financial institutions, governments, and governmental agencies. The company's business consists of Wealth Management*, Investment Management, and Wholesale. The company generates the majority of its revenue from the wholesale segment. The Wholesale Division consists of two businesses, Global Markets, which is mainly engaged in the trading, sales, and structuring of financial products, and Investment Banking, which is engaged in advisory, financing, and solutions businesses.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.